Literature DB >> 21883834

Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score.

Tetsuya Fujimura1, Haruki Kume, Hiroaki Nishimatsu, Toru Sugihara, Akira Nomiya, Yuzuri Tsurumaki, Hideyo Miyazaki, Motofumi Suzuki, Hiroshi Fukuhara, Yutaka Enomoto, Yukio Homma.   

Abstract

UNLABELLED: Study Type - Therapy (symptom prevalence). Level of Evidence 2a. What's known on the subject? and What does the study add? The International Prostate Symptom Score (IPSS) has been most commonly used for the symptom assessment of men with lower urinary tract symptoms (LUTS). However, LUTS in men are so variable that they may not be fully captured by the IPSS questionnaire alone. This study has demonstrated that the Core Lower Urinary Tract Symptom Score (CLSS) questionnaire, which addresses 10 important symptoms, is an appropriate initial assessment tool for LUTS in men with various diseases/conditions.
OBJECTIVE: International Prostate Symptom Score (IPSS) has been commonly used to assess lower urinary tract symptoms (LUTS). We have recently developed Core Lower Urinary Tract Symptom Score (CLSS). The aim of this study is to compare IPSS and CLSS for assessing LUTS in men. PATIENTS AND METHODS: Consecutive 515 men fulfilled IPSS and CLSS questionnaires. IPSS QOL Index was used as the QOL surrogate. The clinical diagnoses were BPH (n = 116), BPH with OAB wet (n =80), prostate cancer (n = 128), prostatitis (n = 68), underactive bladder (n = 8), others (n = 72), and controls (e.g., occult blood) (n = 42). Simple statistics and predictability of poor QOL (QOL Index 4 or greater) were examined.
RESULTS: All symptom scores were significantly increased in symptomatic men compared with controls. Scores of corresponding symptoms of two questionnaires were significantly correlated (r = 0.58-0.85, all P < 0.0001). A multivariate regression model to predict poor QOL indicated nine symptoms (daytime frequency, nocturia, urgency, urgency incontinence, slow stream, straining, incomplete emptying, bladder pain and urethral pain) as independent factors. The hazard ratios for bladder pain (2.2) and urgency incontinence (2.0) were among the highest. All the nine symptoms are addressed in CLSS, while three symptoms (urgency incontinence, bladder, and urethral pain) are dismissed in IPSS.
CONCLUSION: CLSS questionnaire is more comprehensive than IPSS questionnaire for symptom assessment of men with various diseases/conditions, although both questionnaires can capture LUTS with possible negative impact on QOL.
© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2011        PMID: 21883834     DOI: 10.1111/j.1464-410X.2011.10445.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  12 in total

Review 1.  Overactive bladder in elderly men: epidemiology, evaluation, clinical effects, and management.

Authors:  Tomas L Griebling
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

2.  Nonspecific genitourinary pain improves after prostatectomy using holmium laser enucleation of prostate in patients with benign prostatic hyperplasia: a prospective study.

Authors:  Sung Han Kim; Seung-June Oh
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

3.  Assessment of lower urinary tract symptoms in Saudi men using the International Prostate Symptoms Score.

Authors:  Mostafa A Arafa; Karim Farhat; Saad Aqdas; Mohamed Al-Atawi; Danny M Rabah
Journal:  Urol Ann       Date:  2015 Apr-Jun

4.  Impact of loop-tail ureteral stents on ureteral stent-related symptoms immediately after ureteroscopic lithotripsy: Comparison with pigtail ureteral stents.

Authors:  Makoto Taguchi; Takaaki Inoue; Kouei Muguruma; Takashi Murota; Hidefumi Kinoshita; Tadashi Matsuda
Journal:  Investig Clin Urol       Date:  2017-10-23

5.  Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH.

Authors:  Salvatore D'Agate; Timothy Wilson; Burkay Adalig; Michael Manyak; Juan Manuel Palacios-Moreno; Chandrashekhar Chavan; Matthias Oelke; Claus Roehrborn; Oscar Della Pasqua
Journal:  World J Urol       Date:  2019-05-11       Impact factor: 4.226

Review 6.  Prevalence, Burden, and Treatment of Lower Urinary Tract Symptoms in Men Aged 50 and Older: A Systematic Review of the Literature.

Authors:  Amy Y Zhang; Xinyi Xu
Journal:  SAGE Open Nurs       Date:  2018-12-26

7.  International Prostatic Symptom Score-voiding/storage subscore ratio in association with total prostatic volume and maximum flow rate is diagnostic of bladder outlet-related lower urinary tract dysfunction in men with lower urinary tract symptoms.

Authors:  Yuan-Hong Jiang; Victor Chia-Hsiang Lin; Chun-Hou Liao; Hann-Chorng Kuo
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

8.  An observational study of the use of beclomethasone dipropionate suppositories in the treatment of lower urinary tract inflammation in men.

Authors:  Giorgio Bozzini; Marco Provenzano; Nicolò Buffi; Mauro Seveso; Giovanni Lughezzani; Giorgio Guazzoni; Alberto Mandressi; Gianluigi Taverna
Journal:  BMC Urol       Date:  2016-06-08       Impact factor: 2.264

9.  Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression.

Authors:  Salvatore D'Agate; Chandrashekhar Chavan; Michael Manyak; Juan Manuel Palacios-Moreno; Matthias Oelke; Martin C Michel; Claus G Roehrborn; Oscar Della Pasqua
Journal:  World J Urol       Date:  2020-12-18       Impact factor: 4.226

10.  Beneficial Effects of Saw Palmetto Fruit Extract on Urinary Symptoms in Japanese Female Subjects by a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.

Authors:  Shizuo Yamada; Michiyo Shirai; Ken Ono; Shinji Kageyama
Journal:  Nutrients       Date:  2022-03-11       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.